Crossover Study to Evaluate the Abuse Potential of Intranasal Esketamine Compared to Racemic Intravenous Ketamine in Nondependent, Recreational Drug Users

NCT02682225 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Drug Abuse

Interventions

DRUG: Intravenous placebo
DRUG: Intranasal placebo
DRUG: Intravenous racemic ketamine
DRUG: Esketamine 112 mg
DRUG: Esketamine 84 mg

Sponsor

Janssen Research & Development, LLC